Cardiac allograft rejection

Surgeon

Volumn 9, Issue 3, 2011, Pages 160-167

  Patel, Jignesh K ^a   Kittleson, Michelle ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibodies; Cardiac allograft vasculopathy; Cardiac transplant; Rejection

Indexed keywords

BIOPSY; ENDOCARDIUM; GRAFT REJECTION; HEART MUSCLE; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; PATHOLOGY; REVIEW; RISK FACTOR;

BIOPSY; ENDOCARDIUM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MYOCARDIUM; RISK FACTORS;

EID: 79960953606     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2010.11.023     Document Type: Review

References (52)

1. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603-6.
2. Oyer PE, Stinson EB, Jamieson SW. Cyclosporine in cardiac transplantation: a 21/2 year follow-up. Transplant Proc; 1983: 2546.
3. Armitage JM, Kormos RL, Griffith BP, Hardesty RL, Fricker FJ, Stuart RS, et al. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc 1991;23:1149-52.
4. Cheung A, Menkis AH. Cyclosporine heart transplantation. Transplant Proc 1998;30:1881-4.
5. Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, et al. The registry of the international society for heart and lung transplantation: twenty-sixth official adult lung and heart-lung transplantation report-2009 J Heart Lung Transplant 2009;28:1031-49.
6. Caves PK, Stinson EB, Graham AF, Billingham ME, Grehl TM, Shumway NE. Percutaneous transvenous endomyocardial biopsy. JAMA 1973;225:288-91.
7. Mehra MR, Parameshwar J. Gene expression profiling and cardiac allograft rejection monitoring: is IMAGE just a mirage? J Heart Lung Transplant; 29:599-602.
8. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in thediagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710-20.
9. Pikul FJ, Bolman RM, Saffitz JE, Chaplin H. Anti-B-mediated rejection of an ABO-incompatible cardiac allograft despite aggressive plasma exchange transfusion. Transplant Proc 1987; 19:4601-4.
10. Ratkovec RM, Hammond EH, O'Connell JB, Bristow MR, DeWitt CW, Richenbacher WE, et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch-preliminary results with plasmapheresis. Transplantation 1992;54:651-5.
11. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-9.
12. Stehlik J, Islam N, Hurst D, Kfoury AG, Movsesian MA, Fuller A, et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant 2009;28:1129-34.
13. Winters GL, Marboe CC, Billingham ME. The International society for heart and lung transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant 1998;17:754-60.
14. Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006;6:150-60.
15. Kirklin JK, Naftel DC, Bourge RC, White-Williams C, Caulfield JB, Tarkka MR, et al. Rejection after cardiac transplantation. A time-related risk factor analysis. Circulation 1992;86(II):236-41.
16. Kobashigawa JA, Kirklin JK, Naftel DC, Bourge RC, Ventura HO, Mohanty PK, et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The transplant cardiologists research database group. J Heart Lung Transplant 1993; 12:355-66.
17. Jarcho J, Naftel DC, Shroyer TW, Kirklin JK, Bourge RC, Barr ML, et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The cardiac transplant research database group. J Heart Lung Transplant 1994;13:583-9
18. discussion 95-6. 1 Kobashigawa JA, Miller L, Yeung A, Hauptman P, Ventura H, Wilensky R, et al. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. Sandoz/ CVIS investigators. J Heart Lung Transplant 1995;14:S221-6.
19. Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22:58-69.
20. Herskowitz A, Soule LM, Ueda K, Tamura F, Baumgartner WA, Borkon AM, et al. Arteriolar vasculitis on endomyocardial biopsy: a histologic predictor of poor outcome in cyclosporine-treated heart transplant recipients. J Heart Transplant 1987;6:127-36.
21. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989;8:430-43.
22. Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006;25:153-9.
23. Kobashigawa JA. Contemporary concepts in noncellular rejection. Heart Fail Clin 2007;3:11-5.
24. Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, Dunlap S, Montpetit M, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005;80:1019-25.
25. Kfoury AG, Stehlik J, Renlund DG, Snow G, Seaman JT, Gilbert EM, et al. Impact of repetitive episodes of antibodymediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 2006;25:1277-82.
26. Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000;19:518-21
27. Hammond EH, Wittwer CT, Greenwood J, Knape WA, Yowell RL, Menlove RL, et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation 1990;50:776-82.
28. Leech SH, Rubin S, Eisen HJ, Mather PJ, Goldman BI, McClurken JB, et al. Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipients. Clin Transplant 2003;17(Suppl. 9):17-26.
29. Toyoda M, Petrosian A, Jordan SC. Immunological characterization of anti-endothelial cell antibodies induced by cytomegalovirus infection. Transplantation 1999;68:1311-8.
30. Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009;28:417-22.
31. Behera SK, Trang J, Feeley BT, Levi DS, Alejos JC, Drant S. The use of Doppler tissue imaging to predict cellular and antibody-mediated rejection in pediatric heart transplant recipients. Pediatr Transplant 2008;12:207-14.
32. Dandel M, Hummel M, Muller J, Wellnhofer E, Meyer R, Solowjowa N, et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. Circulation 2001;104:I184-91.
33. Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson 2009;11:7.
34. Taylor AJ, Vaddadi G, Pfluger H, Butler M, Bergin P, Leet A, et al. Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection. Eur J Heart Fail 2010;12:45-51.
35. Auer T, Schreier G, Hutten H, Schaldach M, Iberer F, Petutschnigg B, et al. Intramyocardial electrograms for monitoring of allograft rejection after heart transplantation. Transplant Proc 1995;27:1983-5.
36. Auer T, Schreier G, Hutten H, Tscheliessnigg KH, Allmayr T, Grasser B, et al. Intramyocardial electrograms for the monitoring of allograft rejection after heart transplantation using spontaneous and paced beats. Transplant Proc 1995; 27:2621-4.
37. Bourge R, Eisen H, Hershberger R, Keller A, Radovancevic B, Schreier G, et al. Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: initial US multicenter experience. Pacing Clin Electrophysiol 1998;21:2338-44.
38. Grasser B, Iberer F, Schaffellner S, Kniepeiss D, Schreier G, Kastner P, et al. Non-invasive graft monitoring after heart transplantation: rationale to reduce the number ofendomyocardial biopsies. Transpl Int 2000;13(Suppl. 1): S225-7.
39. Grasser B, Iberer F, Schreier G, Kastner P, Schaffellner S, Kniepeiss D, et al. Computerized heart allograft-recipient monitoring: a multicenter study. Transpl Int 2003;16:225-30.
40. Gleissner CA, Klingenberg R, Nottmeyer W, Zipfel S, Sack FU, Schnabel PA, et al. Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups. Clin Transplant 2003;17:284-91.
41. Avello N, Molina BD, Llorente E, Bernardo MJ, Prieto B, Alvarez FV. N-terminal pro-brain natriuretic peptide as a potential non-invasive marker of cardiac transplantation rejection. Ann Clin Biochem 2007;44:182-8.
42. Hammerer-Lercher A, Mair J, Antretter H, Ruttmann E, Poelzl G, Laufer G, et al. B-type natriuretic peptide as a marker of allograft rejection after heart transplantation. J Heart Lung Transplant 2005;24:1444.
43. Kittleson MM, Skojec DV, Wittstein IS, Champion HC, Judge DP, Barouch LA, et al. The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients. J Heart Lung Transplant 2009;28:704-9.
44. Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, et al. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J Heart Lung Transplant 2004;23:701-8.
45. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362:1890-900.
46. Mentzer Jr RM, Jahania MS, Lasley RD. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. multicenter FK506 study group. Transplantation 1998; 65:109-13.
47. Onsager DR, Canver CC, Jahania MS, Welter D, Michalski M, Hoffman AM, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999;18:448-55.
48. Kfoury AG, Hammond ME, Snow GL, Drakos SG, Stehlik J, Fisher PW, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 2009;28:781-4.
49. Raichlin E, Edwards BS, Kremers WK, Clavell AL, Rodeheffer RJ, Frantz RP, et al. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J Heart Lung Transplant 2009;28:320-7.
50. Patel JK, Kobashigawa JA. Cardiac allograft vasculopathy. In: Ahsan N, editor. Chronic allograft failure: natural history, pathogenesis, diagnosis and management. Austin: Landes Bioscience; 2008.
51. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N Engl J Med 2003;349:847-58.
52. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694-700.